QIAGEN Hannover GmbH, a prominent subsidiary of QIAGEN N.V., is headquartered in Hannover, Germany. Established in 1986, the company has become a leader in the biotechnology industry, specialising in sample and assay technologies that facilitate molecular diagnostics and life sciences research. With a strong presence in Europe and North America, QIAGEN Hannover is renowned for its innovative products, including nucleic acid extraction kits and PCR assays, which are pivotal in clinical and research settings. The company’s commitment to quality and precision has positioned it as a trusted partner in the healthcare and research sectors. Notable achievements include the development of cutting-edge solutions that enhance the efficiency of genetic testing and biomarker discovery, solidifying QIAGEN's reputation as a key player in the global market.
How does QIAGEN Hannover GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
QIAGEN Hannover GmbH's score of 56 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
QIAGEN Hannover GmbH, headquartered in Germany, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is part of a corporate family that includes Abbott Laboratories, from which it inherits climate-related commitments and performance data. As a merged entity, QIAGEN's climate initiatives and targets are influenced by Abbott Laboratories' sustainability strategies. However, specific reduction targets or achievements for QIAGEN itself have not been disclosed. The absence of documented reduction initiatives or commitments suggests that QIAGEN may still be in the process of establishing its own climate action framework. In the context of industry standards, QIAGEN's climate commitments may align with broader initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are associated with Abbott Laboratories. Nonetheless, without specific data or targets from QIAGEN, it is challenging to assess their individual climate impact or commitments accurately.
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 71% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
QIAGEN Hannover GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.